Abstracts tagged "ACPA"

Abstract Number: 586 • 2016 ACR/ARHP Annual Meeting
Association Between ACPA Fine Specificity and High Resolution Computed Tomography Lung Changes in Patients with Early Rheumatoid Arthritis
Vijay Joshua¹, Katerina Chatzidionysiou¹, Gudrun Reynisdottir¹, Aase Hensvold¹, Monika Hansson¹, Leonor Nogueira², Guy Serre², Johan Grunewald³ and Anca I Catrina¹, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM, Toulouse, France, ³Division of Respiratory Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Airways abnormalities that are consistent with inflammation are common in anti-CCP2 positive subjects without inflammatory arthritis. Anti-CCP2 antibodies are associated with high-resolution computed tomography…
Abstract Number: 1435 • 2015 ACR/ARHP Annual Meeting
Central Pain Sensitization in Rheumatoid Arthritis – Role of ACPA?
Katarzyna Rogoz¹, Teresa Fernandez Zafra¹, Catia Cerqueira², Per Johan Jakobsson³, Katalin Sandor⁴, Erwan Le Maître⁵, Magnus LA. Andersson⁶, K. Lundberg⁷, Camilla Svensson⁴ and Jon Lampa⁸, ¹Physiology and pharmacology, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Dep of Neurology, Karolinska Institute, Stockholm, Sweden, ⁷Karolinska Institute, Stockholm, Sweden, ⁸Dep of Medicine, Rheumatology unit, Karolinska Institute, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Chronic pain continues to be a significant problem for patients with rheumatoid arthritis (RA), even when the disease is medically controlled or in remission.…
Abstract Number: 3100 • 2015 ACR/ARHP Annual Meeting
Anti-RA33 Citrullinated/Native Double-Reactive Antibodies Identify Patients with the Highest Risk of Radiographic Progression in Rheumatoid Arthritis
Maximilian F. Konig¹, Jon Giles², Peter A. Nigrovic³ and Felipe Andrade¹, ¹Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Antibodies against RA33 (hnRNP A2/B1) were one of the earliest antigen specificities identified in rheumatoid arthritis (RA). Unlike the erosive disease associated with anti-citrullinated…
Abstract Number: 1510 • 2015 ACR/ARHP Annual Meeting
The Association Between HDL Cholesterol Efflux Capacity, Citrullinated ApoA1 and Anti-Citrullinated ApoA1 Antibodies in Rheumatoid Arthritis
Katherine Liao¹, Jing Cui¹, Christopher Rhodes², Lauren J. Lahey², Martin Playford³, I-Hsin Kuo¹, Michelle Frits¹, Christine Iannaccone¹, Jonathan S. Coblyn⁴, Michael Weinblatt¹, Nancy Shadick⁵, Nehal N. Mehta³ and Jeremy Sokolove², ¹Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ²Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ³NHLBI, National Institutes of Health, Bethesda, MD, ⁴Brigham & Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA
Background/Purpose: High density lipoprotein (HDL) cholesterol efflux capacity measures how well HDL particles remove cholesterol from lipid-laden macrophages, such as those found in atherosclerotic plaques. …
Abstract Number: 3172 • 2015 ACR/ARHP Annual Meeting
Effect of Anti Citrullinated Protein Antibodies on Periarticular and Systemic Bone Mass in Early Arthritis Patients
Irene Llorente Cubas*¹, Leticia Merino-Meléndez², Ana M. Ortiz Garcia², Eugenio Escolano³, Teresa Velasco¹, Elena García², Esther Vicente-Rabaneda², Alberto Garcia-Vadillo⁴, Rosario Garcia-Vicuña⁴, Isidoro González-Alvaro*² and Santos Castañeda*², ¹Rheumatology, H.U La Princesa, Madrid, Spain, ²Rheumatology, H.U. La Princesa, Madrid, Spain, ³Radiology Department, H.U La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain
Background/Purpose: Recently it has been described that anti citrullinated protein antibodies (ACPA) can induce differentatiomn and activation of osteoclasts even before arthritis onset (1,2). The…
Abstract Number: 1594 • 2015 ACR/ARHP Annual Meeting
No Association of Anti-Citrullinated Peptide Antibodies with Coronary Artery Calcification in Two Rheumatoid Arthritis Cohorts without Clinical Cardiovascular Disease
Laura Geraldino-Pardilla¹, Jon T. Giles², Jeremy Sokolove³, Afshin Zartoshti⁴, WH Robinson⁵ and Joan M. Bathon⁶, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ⁴Rheumatology, Columbia University Medical Center, NY, NY, ⁵Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁶Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Citrullinated proteins have been found in atherosclerotic plaques. However, contradictory results currently exist regarding the association of anti-citrullinated peptide antibodies (ACPAs) with coronary artery…
Abstract Number: 3253 • 2015 ACR/ARHP Annual Meeting
The Predictive Value of Antibodies to Cyclic Citrullinated Peptide in Two Prospective Early Rheumatoid Arthritis Cohorts 10 Years Apart
Alf Kastbom¹, Michael Ziegelasch¹, Ingrid Thyberg¹, Birgir Arge², Klara Martinsson¹, Olle Svernell³, Åsa Häggström⁴, Per Salomonsson⁵, Britt-Marie Nyhäll-Wåhlin⁶, Sören Transö⁷, Claudia Jacobs⁸ and Thomas Skogh¹, ¹IKE/Rheumatology, Linköping University, Linköping, Sweden, ²Rheumatology clinic, Eskilstuna Hospital, Eskilstuna, Sweden, ³Rheumatology Dpt, Västervik Hospital, Västervik, Sweden, ⁴Rheumatology clinic, Kalmar Hospital, Kalmar, Sweden, ⁵Rheumatology Clinic, Örebro University Hospital, Örebro, Sweden, ⁶Department of Rheumatology, Falun Hospital, Falun, Sweden, ⁷Rheumatology Clinic, Ryhov Hospital, Jönköping, Sweden, ⁸Rheumatology Dept, Oskarshamn Hospital, Oskarshamn, Sweden
Background/Purpose: Antibodies to cyclic citrullinated peptides (anti-CCP) associate with a more severe rheumatoid arthritis (RA) disease course, and therefore have influence on therapeutic decisions. By…
Abstract Number: 151 • 2015 ACR/ARHP Annual Meeting
Residual Synovitis in Ultrasound (US) Is Associated with an Evolution Towards Rheumatoid Arthritis (RA) in Patients with Inflammatory Polyarthralgia without ANTI-Citrulinated Antibodies (ACPA)
Pascal Zufferey^1,2,3, Claudia Rebell Jr.⁴, Alexandre Dumusc⁵, Mauro lucini⁴, Juerg Hains⁶, Alexander K. So Sr.⁷ and Charles Benaim⁸, ¹Rheumatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ²Pierer Decler, Chuv, Lausanne, Switzerland, ³Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland, ⁴DAL, RHU/CHUV, lausanne, Switzerland, ⁵RHU/CHUV, lausanne, Switzerland, ⁶DAL, RHU/CHUV, Lausanne, Syria, ⁷Service De Rhumatologie, CHUV, Lausanne, Switzerland, ⁸DAL, MPR, Lausanne, Switzerland
Background/Purpose: In ACPA positive patients, subclinical synovitis as observed by US has been demonstrated in pre RA patients and seems to be predictive for future…
Abstract Number: 1618 • 2015 ACR/ARHP Annual Meeting
The Protective Effect of HLA-DRB1*13 Alleles during Specific Phases in the Development of ACPA-Positive RA
J. van Heemst¹, A.H. Hensvold², X. Jiang², H. van Steenbergen¹, L. Klareskog², T. W. J. Huizinga¹, A.H.M. van der Helm- van Mil¹, A.I. Catrina², René E. M. Toes¹, K. Lundberg² and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Karolinska Institute, Stockholm, Sweden
Background/Purpose: HLA-DRB1*13 alleles are associated with protection from anti-citrullinated protein antibody (ACPA-)positive rheumatoid arthritis (RA). It is however unknown at which phase of disease development…
Abstract Number: 479 • 2015 ACR/ARHP Annual Meeting
How to Recruit Anti-CCP Positive Patients from Primary Care
Jackie L. Nam¹, Laura Hunt¹, Elizabeth M.A. Hensor¹ and Paul Emery^1,2, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom
Background/Purpose: Around 1% of the population test positive for anti-cyclic citrullinated peptide (anti-CCP) antibodies. This biomarker predicts progression to rheumatoid arthritis (RA) but over a…
Abstract Number: 1641 • 2015 ACR/ARHP Annual Meeting
B Cell Depletion with Rituximab in Patients with Rheumatoid Arthritis: Multiplex Bead Array Reveals Kinetics of IgG and IgA Autoantibodies to Citrullinated Antigens
Geraldine Cambridge¹, Lauren J. Lahey², Maria J. Leandro¹, William H. Robinson³ and Jeremy Sokolove⁴, ¹Rheumatology, University College London, London, United Kingdom, ²Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ³VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁴Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA
Background/Purpose: Seropositivity for rheumatoid factors and anti-citrullinated (Cit) protein antibodies (ACPA) are the strongest predictor for clinical response to rituximab (RTX) in rheumatoid arthritis (RA).…
Abstract Number: 499 • 2015 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab Monotherapy in Patients with RA Is Not Influenced By ACPA Positivity
Manfred Herold¹, Peter Fasching², Winfried Graninger³, Raimund Lunzer⁴, Omid Zamani⁵ and Burkhard Leeb⁶, ¹Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, ²Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, ³Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁴Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, ⁵Rheumazentrum Favoriten Vienna, Wien, Austria, ⁶2nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria
Background/Purpose: Rheumatoid arthritis (RA) patients with anti-citrullinated peptide antibodies (ACPA) need a more aggressive therapy (1). Tocilizumab (TCZ) seems to be the biologic with best…
Abstract Number: 2020 • 2015 ACR/ARHP Annual Meeting
Elevated BMI and ACPA Together Increase RA Risk and Independently Accelerate Time to RA
Sara K. Tedeschi¹, Jing Cui², Elizabeth V. Arkema³, Jeffrey A. Sparks¹, Elizabeth W. Karlson¹ and Karen H. Costenbader^1,4, ¹Rheumatology, Brigham & Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ³Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Obesity and anti-citrullinated peptide antibodies (ACPA) are risk factors for RA. We investigated whether body mass index (BMI) and ACPA interact in determining RA…
Abstract Number: 515 • 2015 ACR/ARHP Annual Meeting
Are Changes in Autoantibody Levels Reflecting Change in Prognosis of Rheumatoid Arthritis?
Manuel Unger¹, Farideh Alasti¹, Paul Studenic¹, Josef S. Smolen^2,3 and Daniel Aletaha¹, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ³Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) is associated with progression of joint damage in patients with rheumatoid arthritis…
Abstract Number: 2565 • 2015 ACR/ARHP Annual Meeting
ACPA Specific IVIG Attenuate Collagen Induced Arthritis in Mice
Shaye Kivity¹, Nina Svetliscky¹, Qusim Odeh¹, Smadar Gertel¹, Howard Amital¹, Omer Gendelman¹, Iris Barshack², Alexander Volkov², Eran Bar-Meir³, Miri Blank¹ and Yehuda Shoenfeld⁴, ¹Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ²Sheba Medical Center, Institute of Pathology, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ³Plastic surgeon Poria Medical Center affiliated to Faculty of medicine in the Galilee Bar-Ilan university, Poria, Israel, ⁴Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel
Background/Purpose: Administration of intravenous-immunoglobulin (IVIg) is a recognized safe and efficient immunomodulatore therapy for many autoimmune diseases. Anti-idiotypic antibody binding to pathogenic autoantibodies was proposed…

« Previous Page
1
…
5
6
7
8
9
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].